Viking Therapeutics Reports Third-Quarter 2026 Results and Pipeline Update
Viking said its Phase 3 trials of subcutaneous VK2735 in obesity continue to advance, initiated Phase 3 trials of oral VK2735, and reported positive top-line results from a VK2735 maintenance-dosing study, with Part 2 initiated. A Phase 1 single-ascending-dose study of VK3019 is nearing completion.
Story updates
08:07:40 PM UTC
SquawkNews
Viking Therapeutics 3Q Loss/Shr $1.55 >VKTX
08:08:16 PM UTC
SquawkNews
Viking Therapeutics reported Q3 2026 net loss of $183.2M ($1.55/share) vs. $90.8M a year ago, with cash, cash equivalents and short-term investments of $960M. The company advanced Phase 3 programs for VK2735, initiated oral SUNRISE trials, and expanded maintenance studies.Material DetailsContext by…
VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance ---- SUNRISE Phase 3 Trials for Oral VK2735 Initiated ---- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part 2 Study Initiated ---- Phase 1 SAD Study of Amylin Agonist VK3019 Nearing Comple…